Maravai Lifesciences Holdings (MRVI) Receivables (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Receivables of $33.4 million for Q1 2026, up 17.27% year-over-year from $28.5 million in Q1 2025, and up 31.05% quarter-over-quarter from $25.5 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Receivables (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Receivables history runs 7 years deep, the most recent figure standing at $33.4 million for Q1 2026.
- In Q1 2026, Receivables rose 17.27% year-over-year to $33.4 million; the TTM figure through Mar 2026 stood at $33.4 million (up 17.27% YoY), while the FY2025 annual figure was $25.5 million, down 35.04% from the prior year.
- Receivables for Q1 2026 stood at $33.4 million, up from $25.5 million in the prior quarter.
- The five-year high for Receivables was $120.4 million in Q1 2022, with the low at $22.5 million in Q3 2025.
- The 5-year median for Receivables is $38.7 million (2024), against an average of $52.3 million.
- The sharpest annual moves came in 2022 and 2023: Receivables surged 72.99% in 2022, then slumped 59.96% in 2023.
- Maravai Lifesciences Holdings' Receivables stood at $114.1 million in 2022, then slumped by 54.24% to $52.2 million in 2023, then retreated by 27.49% to $37.8 million in 2024, then plunged by 32.62% to $25.5 million in 2025, then surged by 31.05% to $33.4 million in 2026.
- Business Quant data shows MRVI's Receivables at $33.4 million in Q1 2026, $25.5 million in Q4 2025, and $22.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 31.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.14 Mn |
| Mar 31, 2026 | 33.42 Mn |
| Dec 31, 2025 | 25.50 Mn |
| Sep 30, 2025 | 22.54 Mn |
| Jun 30, 2025 | 27.88 Mn |
| Mar 31, 2025 | 28.49 Mn |
| Dec 31, 2024 | 37.84 Mn |
| Sep 30, 2024 | 28.79 Mn |
| Jun 30, 2024 | 34.74 Mn |
| Mar 31, 2024 | 39.53 Mn |
| Dec 31, 2023 | 52.20 Mn |
| Sep 30, 2023 | 45.67 Mn |
| Jun 30, 2023 | 48.99 Mn |
| Mar 31, 2023 | 56.89 Mn |
| Sep 30, 2022 | 114.07 Mn |
| Jun 30, 2022 | 120.35 Mn |
| Mar 31, 2022 | 120.36 Mn |
| Sep 30, 2021 | 65.94 Mn |
| Jun 30, 2021 | 83.53 Mn |
| Mar 31, 2021 | 122.82 Mn |